Medicine & Life Sciences

1. Venous Thromboembolism 100%
2. Anticoagulants 39%
3. Thrombosis 38%
4. Neoplasms 32%
5. Rivaroxaban 31%
6. apixaban 23%
7. Pulmonary Embolism 22%
8. Hemorrhage 21%
9. Cohort Studies 19%
10. Dabigatran 18%
11. Venous Thrombosis 18%
12. Thromboembolism 17%
13. edoxaban 16%
14. Consensus 15%
15. Rosuvastatin Calcium 14%
16. Thrombocytopenia 14%
17. Randomized Controlled Trials 13%
18. Antiphospholipid Syndrome 13%
19. Therapeutics 12%
20. Low Molecular Weight Heparin 11%
21. Prospective Studies 11%
22. Feasibility Studies 11%
23. Acute Myeloid Leukemia 10%
24. Heparin 10%
25. Evaluation Studies 9%
26. NVP-BKM120 9%
27. Cost-Benefit Analysis 9%
28. Early Detection of Cancer 9%
29. romidepsin 8%
30. Second Primary Neoplasms 8%
31. Postthrombotic Syndrome 8%
32. fibrin fragment D 8%
33. Tomography 8%
34. Raptors 8%
35. Pelvic Neoplasms 7%
36. Central Venous Catheters 7%
37. Network Meta-Analysis 7%
38. Tetraploidy 7%
39. 70-kDa Ribosomal Protein S6 Kinases 7%
40. Atrial Fibrillation 6%
41. Hematology 6%
42. Antithrombins 6%
43. Idiopathic Thrombocytopenic Purpura 6%
44. Oral Surgery 6%
45. Needs Assessment 6%
46. Vitamin K 6%
47. Lymphoma, Large B-Cell, Diffuse 5%
48. Abdomen 5%
49. Safety 5%
50. gemcitabine 5%